BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/20/2021 12:49:51 PM | Browse: 679 | Download: 2033
 |
Received |
|
2020-09-21 05:56 |
|
Peer-Review Started |
|
2020-09-21 05:56 |
|
First Decision by Editorial Office Director |
|
2020-11-16 21:41 |
|
Return for Revision |
|
2020-11-16 21:41 |
|
Revised |
|
2020-11-25 22:16 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-01-27 06:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-03-08 03:38 |
|
Articles in Press |
|
2021-03-08 03:38 |
|
Edit the Manuscript by Language Editor |
|
2021-03-22 22:19 |
|
Typeset the Manuscript |
|
2021-04-15 01:31 |
|
Publish the Manuscript Online |
|
2021-04-20 12:49 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neo-adjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kosuke Suzuki, Tsuyoshi Etoh, Tomotaka Shibata, Kohei Nishiki, Shoichi Fumoto, Yoshitake Ueda, Hidefumi Shiroshita, Norio Shiraishi and Masafumi Inomata |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kosuke Suzuki, PhD, Assistant Professor, Department of Gastroenterological and Pediatric Surgery, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan. kosuzuki@oita-u.ac.jp |
| Key Words |
Esophageal cancer; Neoadjuvant chemotherapy; Positron emission tomography/computed tomography; Complete metabolic response; Prognostic factor; Docetaxel, cisplatin plus 5-FU |
| Core Tip |
The study aimed to evaluate the value of Positron emission tomography (PET)/computed tomography complete metabolic response (CMR) as a prognostic predictor for esophageal cancer. Fifty-eight patients with esophageal cancer who underwent neoadjuvant chemotherapy in Oita University were enrolled. The PET-CMR group included 22 patients, and the Non-PET-CMR group included 36 patients. Five-year relapse-free survival (RFS) and overall survival in the PET-CMR group were significantly more favorable than those in the Non-PET-CMR group. PET-CMR was a significant prognostic factor in terms of RFS by univariate analysis. PET-CMR after neoadjuvant chemotherapy is considered a favorable prognostic factor for RFS in patients with esophageal cancer. |
| Publish Date |
2021-04-20 12:49 |
| Citation |
Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neo-adjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i4.249 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
